Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) and C3 Glomerulopathy (C3G)

IC-MPGN and C3G are rare kidney diseases. In both diseases, an important part of the immune system known as the complement cascade is overactive, which results in the excessive breakdown of a protein called C3.1 These C3 breakdown products become trapped in the kidney, causing inflammation and damage to the organ.1

Although IC-MPGN is a distinct disease from C3G, the underlying cause and progression of the two diseases are remarkably similar.2,3 The signs and symptoms of IC-MPGN and C3G include blood in the urine (hematuria); dark foamy urine due to the presence of protein (proteinuria); edema (swelling), often in the legs, although any part of the body can be affected; high blood pressure; and decreased urine output.4

There are no therapies currently approved for IC-MPGN or C3G, so there is a substantial need for medicines that target the cause of the diseases. IC-MPGN and C3G can lead to kidney failure within five to 10 years of diagnosis in up to 50% of patients, requiring these patients to go on dialysis or get a kidney transplant.5

If you have questions about our clinical trials, please email us at Learn more about ongoing, C3G/IC-MPGN Apellis-sponsored clinical trials below.

Medical Resources

Clinical Trials


Study Sites



  1. Genetics Home Reference. Available at: Accessed November 27, 2019.
  2. Noris M, Donadelli R, Remuzzi G. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. Pediatr Nephrol. 2019 Aug;34(8):1311-1323.
  3. Cook HT. Evolving complexity of complement-related diseases: C3 glomerulopathy and atypical haemolytic uremic syndrome. Curr Opin Nephrol Hypertens. 2018 May;27(3):165-170.
  4. Complement 3 Glomerulopathy (C3G). National Kidney Foundation Website. Accessed November 21, 2019.
  5. C3 glomerulopathy. National Institute of Health, Genetics Home Reference. Accessed Novemer 21, 2019.

You are now leaving

You are about to leave to visit a third-party website. We recommend reviewing the privacy policy and terms & conditions of any site you visit, as Apellis Pharmaceuticals, Inc. is not responsible for their content.